skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
MAGE-A3/HPV 16 Peptide Vaccine (Code C61088)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: MAGE-A3/HPV 16 Peptide Vaccine

Definition: A multi-epitope Trojan antigen (TA) construct vaccine consisting of human melanoma antigen A3 (MAGE-A3) and human papillomavirus (HPV) 16 peptide epitopes linked by the furin-sensitive linker peptide RVKR (arginine-serine-lysine-arginine) with immunostimulatory and antitumor activities. The TA construct enters the cytoplasm of antigen-presenting cells (APC) and is processed by the endoplasmic reticulum (ER) and the trans-Golgi network (TGN), where the endopeptidase furin releases the epitopes from the RVKR linker peptide and, together with various exopeptidases, generates MHC class I-binding peptides. Expressed on the cell surfaces of APC, these MHC class I-binding peptides stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that display the same peptide epitopes on their cell surfaces.

Label: MAGE-A3/HPV 16 Peptide Vaccine

NCI Thesaurus Code: C61088 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831802  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
MAGE-A3/HPV 16 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 478746
PDQ Open Trial Search ID 478746 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831802

Other Properties:
     Name Value (qualifiers indented underneath)
code C61088
Legacy_Concept_Name MAGE-A3_HPV-16_Peptide_Vaccine
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom